{
    "clinical_study": {
        "@rank": "149850", 
        "arm_group": [
            {
                "arm_group_label": "Belatacept", 
                "arm_group_type": "Active Comparator", 
                "description": "Belatacept 10mg/kg administered intravenously on days 1, 4, 15, and 28, weeks 8 and 12.  Then continue at 5mg/kg every 4 weeks throughout the completion of the study."
            }, 
            {
                "arm_group_label": "Everolimus", 
                "arm_group_type": "Active Comparator", 
                "description": "Everolimus 1.5 mg/kg twice a day by mouth, the dose will be adjusted after Day  3."
            }
        ], 
        "brief_summary": {
            "textblock": "Currently looking for individuals that have received a kidney transplant, are experiencing\n      delayed graft function (DGF), and meet the criteria for study participation."
        }, 
        "brief_title": "Belatacept for Renal Transplant Recipients With Delayed Graft Function", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Delayed Graft Function", 
        "condition_browse": {
            "mesh_term": "Delayed Graft Function"
        }, 
        "detailed_description": {
            "textblock": "Patients who undergo kidney transplantation require long term immunosuppressive  therapy\n      (therapy that reduces your body's ability to respond to anything foreign) to prevent damage\n      to the graft, and some experience delayed graft function (DGF, a condition in which the\n      transplanted kidney does not function properly) after transplantation.  This study is being\n      conducted to determine if kidney transplant recipients with delayed graft function (DGF) who\n      are switched to the immunosuppressive regimen of belatacept with mycophenolate and steroid\n      will recover from delayed graft function (DGF) in less time (which could potentially lower\n      the risk of rejection associated with delayed graft function) than kidney transplant\n      recipients with delayed graft function (DGF) who remain on the current standard\n      immunosuppressive regimen (standard of care)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed Written Informed Consent\n\n          2. Deceased donor renal transplant recipient\n\n          3. Men and women, aged 18-60 years of age\n\n        Exclusion Criteria:\n\n          1. Seronegative or unknown EBV serostatus\n\n          2. Patients unwilling or incapable of providing informed consent.\n\n          3. Patients with active tuberculosis or positive TB test without evidence of infection\n             treatment.\n\n          4. Patients with demonstrated acute rejection on first biopsy evaluation for delayed\n             graft function; Second transplant or multiple organ transplant; patients more than 12\n             days post renal transplant prior to enrollment\n\n          5. Evidence of Sepsis or other clinical indicators deemed clinically contraindicated for\n             study enrollment by the primary physician\n\n          6. Inadequate vein access to receive monthly IV infusions\n\n          7. Prior proven allergy or severe adverse drug reaction to mycophenolate, steroid or\n             Belatacept preventing therapy.\n\n          8. Pregnant women or women of child bearing age not willing to commit to dual\n             contraception prophylaxis\n\n          9. Use of alemtuzumab (Campath 1-H\u00a9), basilixumab (Simulect\u00a9) and daclizumab (Zenapax\u00a9)\n             are not permitted in this protocol; Use of other immunosuppressive agents must be\n             limited to those specified in this protocol.\n\n         10. Prisoners or subjects who are involuntarily incarcerated.\n\n         11. Subjects who are compulsorily detained for treatment of either a psychiatric or\n             physical (eg, infectious disease) illness.\n\n         12. Pre-sensitized patients with alloscreen antibody levels of 80% or more class I or\n             class II"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134288", 
            "org_study_id": "IM103-336", 
            "secondary_id": "2013H0312"
        }, 
        "intervention": [
            {
                "arm_group_label": "Belatacept", 
                "intervention_name": "Belatacept", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Everolimus", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus", 
                "Abatacept"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Dialysis", 
            "Kidney Transplant", 
            "immunosuppressive therapy", 
            "Delayed Graft Function", 
            "Belatacept"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "contact": {
                "email": "jerry.phalan@osumc.edu", 
                "last_name": "Jerry Phalan", 
                "phone": "614-293-4665"
            }, 
            "facility": {
                "address": {
                    "city": "Columbus", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "43212"
                }, 
                "name": "The Ohio State Universtiy Wexner Medical Center"
            }, 
            "investigator": {
                "last_name": "Jon Von Visger, M.D./Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective, Randomized Trial of Belatacept Switch in Renal Transplant Recipients With Delayed Graft Function", 
        "overall_contact": {
            "email": "jerry.phalan@osumc.edu", 
            "last_name": "Jerry Phalan", 
            "phone": "614-293-4665"
        }, 
        "overall_official": {
            "affiliation": "OSU Wexner Medical Center", 
            "last_name": "Jon Von Visger, M.D./Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "For renal transplant recipients with DGF, time (days) to recover from DGF as defined as: date of enrollment (day 1) until calculated MDRD IV eGFR at least 21 ml/min: at least 2 days after last dialysis if meeting dialysis criteria for enrollment (end date) and no requirement for dialysis at least 2 weeks, with a stable or improving MDRD calculated eGFR (assessed weekly for at least three weeks).", 
            "measure": "Time to recover from Delayed Graft Function", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134288"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Ohio State University", 
            "investigator_full_name": "Von Visger, Jon, MD", 
            "investigator_title": "Assistant Professor of Internal Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Percent patients reaching recovery (defined above) by 14 days and 3 months.", 
                "measure": "Percent patients reaching recovery (defined above) by 14 days and 3 months.", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 3, 6, 12 months"
            }, 
            {
                "description": "by monitoring patient while inpatient", 
                "measure": "Hospital length of stay (days) from date of transplant to discharge", 
                "safety_issue": "No", 
                "time_frame": "up to 7 days"
            }, 
            {
                "description": "by monitoring patients health at each visit, and notification of hospitalizations/AE's", 
                "measure": "Number of dialysis treatments", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 3, 6, 12 months"
            }, 
            {
                "description": "medical record review of clinically indicated renal allograft biopsies performed within the followup 12 month period", 
                "measure": "Number of biopsies", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 3, 6, 12 months"
            }, 
            {
                "description": "by blood draws, and by monitoring patients health at each visit, and notification of hospitalizations/AE's", 
                "measure": "Biopsy proven acute rejection events", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 3, 6, 12 months"
            }, 
            {
                "description": "by monitoring patients health at each visit, and notification of hospitalizations/AE's", 
                "measure": "Patient and graft survival", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 3, 6, 12 months"
            }, 
            {
                "description": "by monitoring patients health at each visit, and notification of hospitalizations/AE's", 
                "measure": "Number of hospital readmissions", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 3, 6, 12 months"
            }, 
            {
                "description": "by blood draw", 
                "measure": "Detection of DSA (Luminex)", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 3, 6, 12 months"
            }, 
            {
                "description": "by monitoring patients health at each visit, and notification of hospitalizations/AE's", 
                "measure": "Incidence and type of infection", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 3, 6, 12 months"
            }, 
            {
                "description": "by blood draw", 
                "measure": "Measured or estimated creatinine clearance.", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 3, 6, 12 months"
            }, 
            {
                "description": "by monitoring patients health at each visit, and notification of hospitalizations/AE's", 
                "measure": "Banff score of rejection episodes and immune suppression treatment/management of rejection", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 3, 6, 12 months"
            }, 
            {
                "description": "by blood draw, and by monitoring patients health at each visit, and notification of hospitalizations/AE's", 
                "measure": "Immune suppression drug levels (everolimus or sirolimus, cyclosporine, or mycophenolate as clinically monitored).", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 3, 6, 12 months"
            }
        ], 
        "source": "Ohio State University", 
        "sponsors": {
            "collaborator": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Von Visger, Jon, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}